Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study

Table 3 Comparison of QoL scores between regimens based on nevirapine or efavirenz over the follow-up period using GEE

QoL summary score	β coefficient (95 % CI)	β coefficient (95 % CI)
	OR (95 % CI)	OR (95 % CI)
	unadjusted	Adjusted
PHS
CD4 count <100 cells/μl
NVP	Ref	Ref
EFV	−1.61(−2.82 to −0.40)	−1.61 (−2.74 to −0.49)^a
EFV	−1.61(−2.82 to −0.40)	P = 0.11^d
CD4 count 101–250 cells/μl
NVP	Ref	Ref
EFV	0.17 (−0.70 to 1.05)	0.82 (0.22 to 1.43)^a
EFV	0.17 (−0.70 to 1.05)	P = 0.76^d
CD4 count >250 cells/μl
NVP	Ref	Ref
EFV	0.97 (−0.35 to 2.30)	−1.33 (−5.66 to 3.00)^a
EFV	0.97 (−0.35 to 2.30)	P = 0.90^d
MHS
CD4 count <100 cells/μl
NVP	Ref	Ref
EFV	−0.18 (−1.18 to 0.82)	−0.39 (−1.40 to 0.62)^b
EFV	−0.18 (−1.18 to 0.82)	P = 0.91^d
CD4 count 101–250 cells/μl
NVP	Ref
EFV	−0.09 (−0.93 to 0.75)	0.16 (−0.66 to 0.98)^b
EFV	−0.09 (−0.93 to 0.75)	P = 0.78^d
CD4 count >250 cells/μl
NVP	Ref	Ref
EFV	−0.84 (−2.09 to 0.42)	−0.75 (−2.01 to 0.51)^b
EFV	−0.84 (−2.09 to 0.42)	P = 0.65^d
GPGI
CD4 count <100 cells/μlEFV versus NVP
	−0.59 (0.31 to 1.13)	0.51 (0.25 to1.04)^c
	−0.59 (0.31 to 1.13)	P = 0.54^d
CD4 count 101–250 cells/μl
EFV versus NVP	0.85 (0.54 to 1.33)	0.98 (0.60 to 1.56)^c
EFV versus NVP	0.85 (0.54 to 1.33)	P = 0.08^d
CD4 count >250 cells/μl
EFV versus NVP	1.30 (0.66 to 2.56)	1.39 (0.66 to 2.90)^c
EFV versus NVP	1.30 (0.66 to 2.56)	P = 0.08^d

^aadjusted for age, study visit, diagnosis of depression, income per month, WHO stage, education level and opportunistic infection
^badjusted for sex, age, study visit, WHO stage, marital status, social support and level of education
^cadjusted for sex, age, study visit, WHO stage, education level, income per month, depression, employment status, alcohol use, social support and opportunistic infection
^dP value for interaction term (time*ART regimen)

ISSN: 1472-6963